In the claims:

1. (Currently amended) A human coagulation Factor VII variant comprising a substitution of the Leu in position 305 of SEQ ID NO 1 with an amino acid residue selected from the group consisting of Val, Ile, Met, Phe, Trp, Pro, Gly, Ser, Thr, Cys, Tyr, Asn, Glu, Lys, Arg, His, Asp and Gln, wherein the ratio between the activity of the variant and the activity of native Factor VII polypeptide having a sequence shown in SEQ ID NO 1 is at least about 1.25 when tested in an *in vitro* hydrolysis assay.

2. (Original) A Factor VII variant as defined in claim 1, wherein the substituted amino acid is selected from the group consisting of Val, Tyr, and Ile.

3. (Original) A Factor VII variant as defined in claim 1, further comprising a second substitution selected from the group consisting of (i) position 274; (ii) any of positions 300-304; (iii) any of positions 306-312; and (iv) combinations of any of the foregoing.

4. (Original) A Factor VII variant as defined in claim 3, wherein the second substitution is at position 274.

5. (Original) A Factor VII variant as defined in claim 3, wherein the second substitution is at any of positions 300-304.

6. (Original) A Factor VII variant as defined in claim 3, wherein the second substitution is at any of positions 306-312.

7. (Original) A Factor VII variant as described in claim 1, wherein the Leu residue in position 305 is the only amino acid residue that has been replaced relative to the sequence of SEQ ID NO:1.

8. (Original) A human coagulation Factor VII variant, comprising a substitution of the Leu in position 305 of SEQ ID NO 1 with Val.

9. (Original) A human coagulation Factor VII variant, comprising a first substitution of the Leu in position 305 of SEQ ID NO 1 with Val and a second substitution selected from the group consisting of: (i) substitution of Ala 274 with Met, Leu, Lys, or Arg; (ii) substitution of Arg 304 with Tyr, Phe, Leu, or Met; (iii) substitution of Met 306 with Asp or Asn; (iv) substitution of Asp 309 with Ser or Thr, and (iv) combinations of any of the foregoing.

10. (Cancelled)

11. (Currently amended) A Factor VII variant as defined in claim ~~10~~ 1, wherein the ratio is at least about 2.0.

12. (Currently amended) A Factor VII variant as defined in claim ~~10~~ 1, wherein the ratio is at least about 4.0.

13. (Original) A human coagulation Factor VII variant comprising a substitution of the Leu in position 305 of SEQ ID NO 1 with an amino acid residue selected from the group consisting of Val, Tyr, and Ile, wherein the ratio between the activity of the variant and the activity of native Factor VII polypeptide having a sequence shown in SEQ ID NO 1 is at least about 1.25 when tested in an *in vitro* hydrolysis assay.

14.-23. Cancelled

24. (Original) A pharmaceutical composition comprising (i) a human coagulation Factor VII variant as defined in claim 1 and (ii) a pharmaceutically acceptable carrier or excipient.

25. (Original) A pharmaceutical composition comprising (i) a human coagulation Factor VII variant as defined in claim 2 and (ii) a pharmaceutically acceptable carrier or excipient.

26. (Original) A pharmaceutical composition comprising (i) a human coagulation Factor VII variant as defined in claim 3 and (ii) a pharmaceutically acceptable carrier or excipient.

27. (Original) A pharmaceutical composition comprising (i) a human coagulation Factor VII variant as defined in claim 7 and (ii) a pharmaceutically acceptable carrier or excipient.

28. (Original) A pharmaceutical composition comprising (i) a human coagulation Factor VII variant as defined in claim 8 and (ii) a pharmaceutically acceptable carrier or excipient.

29. Cancelled

30. (New) A method for the treatment of bleeding episodes in a subject or for the enhancement of the normal haemostatic system, the method comprising administering to a subject in need of such treatment a therapeutically or prophylactically effective amount of a human coagulation Factor VII variant as defined in claim 1.

31. (New) A method for the treatment of bleeding episodes in a subject or for the enhancement of the normal haemostatic system, the method comprising administering to a subject in need of such treatment a therapeutically or prophylactically effective amount of a human coagulation Factor VII variant as defined in claim 8.